Skip to main content
Clinical Trials/NCT02088918
NCT02088918
Completed
Phase 1

A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

IlDong Pharmaceutical Co Ltd1 site in 1 country40 target enrollmentOctober 2012

Overview

Phase
Phase 1
Intervention
Nateglinide
Conditions
Healthy Volunteers
Sponsor
IlDong Pharmaceutical Co Ltd
Enrollment
40
Locations
1
Primary Endpoint
AUC last
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

A Randomized, Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared with a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet under Fasting Conditions in Healthy Male Subjects

Registry
clinicaltrials.gov
Start Date
October 2012
End Date
December 2012
Last Updated
12 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age between 20 and 40
  • Signed informed consent

Exclusion Criteria

  • Has a history of hypersensitivity to IP ingredients
  • Hypertension or hyportension

Arms & Interventions

Nateglinide+Metformin

coadministration of nateglinide and metformin

Intervention: Nateglinide

Nateglinide+Metformin

coadministration of nateglinide and metformin

Intervention: Metformin

Nateglinide/Metformin

Nateglinide/Metformin tablet

Intervention: Nateglinide/Metformin

Outcomes

Primary Outcomes

AUC last

Time Frame: 0-~24hrs

Cmax

Time Frame: 0~24hrs

Study Sites (1)

Loading locations...

Similar Trials